EUVIMEDOpdag EUVIMED
Crossref

Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB

Mei Yang, Qian Liu, Aili Xuan iD

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70140 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Mei Yang and 2 co-authors. Institution: Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Major MEDLINE topics: Toll-Like Receptor 4, Acute Lung Injury, NF-kappa B, Hyperoxia. 40 references. Funded by: the First Affiliated Hospital of Bengbu Medical University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hyperoxia‐induced acute lung injury (ALI) in neonates is driven by oxidative stress and inflammation. This study aims to evaluate the efficacy and underlying mechanisms of Relaxin‐2 (RLX‐2) in a neonatal rat model of hyperoxia‐induced ALI. Neonatal Wistar rats were exposed to 90% O 2 for one week and treated with RLX‐2 (0.5 mg/kg/day) via an osmotic pump. Methods included histopathology (hematoxylin–eosin staining), bronchoalveolar lavage fluid (BALF) analysis, Enzyme‐Linked Immunosorbent Assay (ELISA) for interleukin‐1β (IL‐1β), monocyte chemoattractant protein‐1 (MCP‐1), and tumor necrosis factor‐α (TNF‐α), oxidative stress markers [malondialdehyde (MDA) and superoxide dismutase (SOD)], and Western blotting for Toll‐like Receptor 4 (TLR4), Nuclear Factor‐kappa B (NF‐κB), and Sirtuin 1 (SIRT1). Human alveolar epithelial cells (HPAEpiCs) underwent assays using Cell Counting Kit‐8 (CCK‐8), 2′,7′‐Dichlorofluorescin diacetate (DCFH‐DA), and quantitative real‐time polymerase chain reaction (qRT‐PCR). RLX‐2 mitigated alveolar damage and inflammatory infiltration in neonatal rats with hyperoxia‐induced acute lung injury. It decreased cytokine levels, reduced MDA levels, and enhanced SOD activity, thereby alleviating oxidative stress. RLX‐2 suppressed TLR4/NF‐κB signaling by reducing p65 and Myeloid Differentiation Primary Response 88 (MyD88) expression and upregulated SIRT1. SIRT1 silencing abolished RLX‐2's effects, confirming its role in attenuating OS and inflammation. These findings demonstrated RLX‐2's efficacy in neonatal ALI via SIRT1‐dependent TLR4/NF‐κB inhibition, highlighting therapeutic potential.

Subjects

MeSH terms (MEDLINE)

Toll-Like Receptor 4Acute Lung InjuryNF-kappa BHyperoxiaRelaxinAnimalsRatsAnimals, NewbornRats, WistarHumansOxidative StressSignal TransductionSirtuin 1Bronchoalveolar Lavage Fluid

Author keywords

NF‐κBRelaxin‐2SIRT1acute lung injuryinflammationneonates

Substances

Toll-Like Receptor 4NF-kappa BRelaxinSirtuin 1Tlr4 protein, rat

Authors and institutions

  • Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Pediatrics, Shandong Second Medical University Affiliated Hospital, Weifang, Shandong, China.

ORCID profiles: Aili Xuan

Funding

  • the First Affiliated Hospital of Bengbu Medical University

Cite

APA

Yang, M., Liu, Q., & Xuan, A. (2025). Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70140

Vancouver

Yang M, Liu Q, Xuan A. Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70140

BibTeX
@article{Yang2025,
  author = {Yang, Mei and Liu, Qian and Xuan, Aili},
  title = {Relaxin‐2 Alleviates Hyperoxia‐Induced Acute Lung Injury in Neonatal Rats by Inhibiting TLR4/NF‐κB},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70140}
}
Start for free →